The Captopril-Induced Eruption: A Possible Mechanism: Cutaneous Kinin Potentiation

Archives of Dermatology

Volumn 116, Issue 8, 1980, Pages 902-905

  Wilkin, Jonathan K ^a   Hammond, Jeremy J ^a   Kirkendall, Walter M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPHENHYDRAMINE; FUROSEMIDE; KALLIKREIN; KININ; PENICILLIN G; PROPRANOLOL;

ADVERSE DRUG REACTION; CARDIOVASCULAR SYSTEM; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG THERAPY; ERYTHEMA; ESSENTIAL HYPERTENSION; MACULAR SKIN LESION; ORAL DRUG ADMINISTRATION; PRURITUS; SKIN; SKIN TEST; SKIN TOXICITY; THERAPY;

AGED; ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CASE REPORT; DRUG ERUPTIONS; FEMALE; HUMAN; HYPERSENSITIVITY; KININS; MALE; MIDDLE AGE; PROLINE; SKIN; SKIN DISEASES; SKIN TESTS; URTICARIA;

EID: 0018975497     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1980.01640320052013     Document Type: Article

References (17)

1. 1. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196:441-444, 1977.
2. 2. Ferguson RK, Turini GA, Brunner HR, et al: A specific orally active inhibitor of angiotensinconverting enzyme in man. Lancet 1:775-778, 1977.
3. 3. Brunner HR, Waeber B, Wauters J-P, et al: Inappropriate renin secretion unmasked by captopril (SQ14,225) in hypertension of chronic renal failure. Lancet 2:704-707, 1978.
4. 4. Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensinconverting enzyme inhibitor SQ14,225 in man. N Engl J Med 298:991-995, 1978.
5. 5. Research Investigator's Brochure (SQ14,225): Clinical Pharmacology of SQ14,225: Interim Phase I Summary. Princeton, NJ, The Squibb Institute for Medical Research, 1978, pp 1-12.
6. 6. Case DB, Atlas SA, Laragh JH, et al: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral convertingenzyme inhibitor (SQ14,225 captopril) in hypertensive patients. Prog Cardiovasc Dis 21:195-206, 1978.
7. 7. Bravo EL, Tarazi RC: Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1:39-46, 1979.
8. 8. McGiff JC, Nasjletti A: Kinins, renal function and blood pressure regulation. Fed Proc 35:172-174, 1976.
9. 9. Nasjletti A, Colina-Chourio J: Interaction of mineralocorticoids, renal prostaglandins and the renal kallikrein-kinin system. Fed Proc 35:189-193, 1976.
10. 10. Nasjletti A, Colina-Chourio J, McGiff JC: Effect of kininase inhibition on canine renal blood flow and sodium excretion. Acta Physiol Lat Am 24:587-591, 1974.
11. 11. Williams GH, Hollenberg NK: Accentuated vascular and endocrine response to SQ20,881 in hypertension. N Engl J Med 297:184-188, 1977.
12. 12. Berova N, Petkov I, Andreev VC: Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor. Br J Dermatol 90:431-434, 1974.
13. 13. Chapman LF, Goodell H, Wolff HG: Increased inflammatory reaction induced by central nervous system activity. Trans Assoc Am Physicians 72:84-110, 1959.
14. 14. DeLaus FV, Winkelmann RK: Kinins in cold urticaria. Arch Dermatol 98:67-74,1968.
15. 15. Michel B, Russell T, Winkelmann RK, et al: Release of kinins from site of wheal-and-flare allergic skin reactions. Int Arch Allergy Appl Immunol 39:616-624, 1970.
16. 16. Chapman LF: Mechanisms of the flare reaction in human skin. J Invest Dermatol 69:88-97, 1977.
17. 17. Winkelmann RK: Molecular inflammation of the skin. J Invest Dermatol 57:197-208, 1971.